Eevia Health, a frontrunner in sustainable health solutions, has secured a repeat order valued at KEUR 50 (KSEK 555) for its FENO-SAMBUCUS™ 7 ORGANIC elderberry extract. This order, placed by Select Ingredients, a San Diego-based specialist in organic ingredients, underscores the growing demand for Eevia's premium products in the competitive U.S. market.

FENO-SAMBUCUS™ 7 ORGANIC stands out due to its high polyphenol content and proven bioactivity, meeting key standards like the United States Pharmacopeia. A recent pre-clinical in vivo test on 138 biomarkers confirmed its superiority over competing extracts, making it a preferred choice for top brands.

The strategic advantage of Eevia's product lies in its advanced purification process, which enhances the extract's potency. With the product readily available in stock, Eevia ensures swift delivery, positively influencing cash flow and strengthening its position in the market.

Founded in 2017, Eevia Health focuses on addressing global health challenges through bioactive compounds from renewable plant materials. The company operates a modern green-chemistry production facility in Finland, emphasizing sustainability and a short value chain.

Given this positive development, investors might consider holding their positions in Eevia Health. The repeat order not only reflects confidence in Eevia's products but also signals potential for future growth in the organic health market.